RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2008; 133(43): 2233-2237
DOI: 10.1055/s-0028-1091266
DOI: 10.1055/s-0028-1091266
Arzneimittel & Pharmakotherapie | Review article
Diabetologie© Georg Thieme Verlag KG Stuttgart · New York
Sitagliptin
DPP-4-Inhibitoren als sinnvolle Erweiterung der oralen Diabetestherapie?Sitagliptin DPP-4 Inhibitors as expedient extension of oral diabetes treatment?Weitere Informationen
Publikationsverlauf
eingereicht: 6.3.2008
akzeptiert: 23.7.2008
Publikationsdatum:
15. Oktober 2008 (online)

Schlüsselwörter
antidiabetische Therapie - Diabetes mellitus - GLP-1 - Inkretin
Keywords
antidiabetic therapy - diabetes mellitus - GLP-1 - incretin
Literatur
- 1
Ahmad S R, Swan J.
Exenatide
and rare adverse events.
N Engl J Med.
2008;
358
1970-1971
MissingFormLabel
- 2
Ahrén B, Schmitz O.
GLP-1 receptor agonists
and DPP-4 inhibitors in the treatment of type 2 diabetes.
Horm
Metab Res.
2004;
36
867-876
MissingFormLabel
- 3
Amori R E, Lau J, Pittas A G.
Efficacy and Safety of Incretin Therapy in Type 2 Diabetes.
Systematic Review and Meta-analysis.
JAMA.
2007;
298
194-206
MissingFormLabel
- 4
Aronoff S L, Berkowitz K, Shreiner B, Want L.
Glukose metabolism and regulation:
beyond insulin and Glukagon.
Diabetes Spectr.
2004;
17
183-190
MissingFormLabel
- 5
Berthold H K, Gouni-Berthold I, Bestehorn K, Böhm M, Krone W.
Kardiovaskuläre Risikofaktoren bei Typ-2-Diabetikern
in Deutschland – ein Versorgungsparadox.
Dtsch
Arztebl.
2007;
104
A861-A867
MissingFormLabel
- 6
Buse J B, Henry R R, Han J. et al .
Effects of exenatide (exendin-4) on glycemic
control over 30 weeks in sulfonylurea-treated patients with type
2 diabetes.
Diabetes Care.
2004;
27
2628-2635
MissingFormLabel
- 7
Deacon C F, Holst J J.
Dipeptidyl peptidase
IV inhibitors: a promising new therapeutic approach for the management
of type 2 diabetes.
Int J Biochem Cell Biol.
2006;
38
831-844
MissingFormLabel
- 8
Elahi D, McAloon-Dyke M, Fukagawa N K. et al .
The insulinotropic actions of Glukose-dependent
insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7 – 37)
in normal and diabetic subjects.
Regul Pept.
1994;
51
63-74
MissingFormLabel
- 9
He Y L, Wang Y, Bullock J M. et al .
Pharmacodynamics of vildagliptin in patients
with type 2 diabetes during OGTT.
J Clin Pharmacol.
2007;
47
633-641
MissingFormLabel
- 10
Henness S, Keam S J.
Vildagliptin.
Drugs.
2006;
66
1989-2001
MissingFormLabel
- 11
Herman G A, Bergman A, Stevens C. et al .
Effect of single oral doses of sitagliptin,
a dipeptidyl peptidase-4 inhibitor, on incretin and plasma Glukose
levels following an oral Glukose tolerance test in patients with
type 2 diabetes.
J Clin Endocrinol Metab.
2006;
91
4612-4619
MissingFormLabel
- 12
Kolligs F, Fehmann H C, Goke R, Goke B.
Reduction of the incretin
effect in rats by the glucagon-like peptide 1 receptor antagonist
exendin (9 – 39) amide.
Diabetes.
1995;
44
16-19
MissingFormLabel
- 13
Lewis J T, Dayanandan B, Habener J F, Kieffer T J.
Glukose-dependent
insulinotropic polypeptide confers early phase insulin release to
oral Glukose in rats: demonstration by a receptor antagonist.
Endocrinology.
2000;
141
3710-3716
MissingFormLabel
- 14
Lyseng-Williamson K A.
Sitagliptin.
Drugs.
2007;
67
587-597
MissingFormLabel
- 15
Mojsov S, Weir G C, Habener J F.
Insulinotropin: glucagon-like peptide I (7 – 37)
co-encoded in the glucagon gene is a potent stimulator of insulin
release in the perfused rat pancreas.
J Clin Invest.
1987;
79
616-619
MissingFormLabel
- 16
Nathan D M.
Finding new treatments for Diabetes – How many, how fast … how
good?.
N Engl J Med.
2007;
356
437-440
MissingFormLabel
- 17
Nauck M A, Heimesaat M M, Orskov C, Holst J J, Ebert R, Creutzfeldt W.
Preserved incretin
activity of glucagon-like peptide 1 [7 – 36
amide] but not of synthetic human gastric inhibitory polypeptide
in patients with type-2 diabetes mellitus.
J Clin Invest.
1993;
91
301-307
MissingFormLabel
- 18
Nauck M A, Homberger E, Siegel E G. et al .
Incretin effects of increasing Glukose
loads in man calculated from venous insulin and C-peptide responses.
J Clin Endocrinol Metab.
1986;
63
492-498
MissingFormLabel
- 19
Nauck M A, Meininger G, Sheng D, Terranella L, Stein P P. Sitagliptin Study 024 Group .
Efficacy and safety
of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with
the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately
controlled on metformin alone: a randomized, double-blind, non-inferiority
trial.
Diabetes Obes Metab.
2007;
9
194-205
MissingFormLabel
- 20
Nielsen L L.
Incretin mimetics and DPP-IV inhibitors for the treatment of
type 2 diabetes.
Drug Discov Today.
2005;
10
703-710
MissingFormLabel
- 21
Orskov C, Holst J J, Knuhtsen S, Baldissera F G, Poulsen S S, Nielsen O V.
Glucagon-like peptides GLP-1 and GLP-2, predicted products of
the glucagon gene, are secreted separately from pig small intestine
but not pancreas.
Endocrinology.
1986;
119
1467-1475
MissingFormLabel
- 22
Pratley R E, Salsali A.
Inhibition of DPP-4:
a new therapeutic approach for the treatment of type 2 diabetes.
Curr Med Res Opin.
2007;
23
919-931
MissingFormLabel
- 23
Reuter H, Erdmann E.
Exenatid – ein
Inkretin-Mimetikum zur Behandlung des Diabetes mellitus Typ 2.
Dtsch Med Wochenschr.
2007;
132
571-574
MissingFormLabel
- 24
Scrocchi L A, Brown T J, MacLusky N. et al .
Glukose intolerance but normal satiety
in mice with a null mutation in the glucagon-like peptide 1 receptor
gene.
Nat Med.
1996;
2
1254-1258
MissingFormLabel
- 25
Toft-Nielsen M B, Damholt M B, Madsbad S. et al .
Determinants of the impaired
secretion of glucagon-like peptide-1 in type 2 diabetic patients.
J Clin Endocrinol Metab.
2001;
86
3717-3723
MissingFormLabel
- 26
Prospective Diabetes Study
(UKPDS) Group .
UK -- Intensive blood-Glukose control
with sulphonylureas or insulin compared with conventional treatment
and risk of complications in patients with type 2 diabetes (UKPDS
33).
Lancet.
1998;
352
837-853
MissingFormLabel
Dr. Jan Matthes
Institut für Pharmakologie, Universität
zu Köln
Gleueler Straße 24
50931
Köln
Telefon: 0221/4785-674
Fax: 0221/4785-022
eMail: jan.matthes@uni-koeln.de